Search Results

Certis Oncology Solutions today announced that it raised $10 million in a Series C funding round, bringing total raised to $42 million.

Certis Oncology Solutions (“Certis”) today announced the launch of CertisAI™, a new predictive medicine platform that utilizes big data, statistical algorithms, and machine learning to predict drug efficacy based on gene expression biomarkers.

Certis Oncology Solutions announced it has been selected as “Overall Immunology Company of the Year” in the third annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services.

Certis Oncology Solutions (“Certis”) today announced that three abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in Orlando, Fla. from April 14-19, 2023.

SOTERIA Precision Medicine Foundation, an organization dedicated to empowering patients, caregivers, and clinicians with the power of precision medicine, today announced a fiscal sponsorship agreement with Certis Oncology Solutions, a San Diego-based precision oncology and translational science company.

Renaissance BioScience is pleased to announce that it has signed a joint development agreement with Certis Belchim, a global leader in the development of crop-protecting biocontrol agents that combat agricultural pests.

Certis Oncology Solutions, a life science technology company, announced today the release of its new cancer model database, BarneyOI™.

Certis provides high-precision translational drug discovery and development services to therapeutics innovators.